

Fig S1. The comparison of different duration of CZL80 treatment on neurological function after photothrombosis. CZL80 ($30 \text{ mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$) or vehicle was intraperitoneally injected daily during Day1-4, Day4-7 or Day1-7 after photothrombosis, and motor function was measured daily. (A) Foot fault of left forelimb in the grid-walking task and (B) Forelimb asymmetry in the cylinder task. All results were represented as means \pm SD ($n=9$ per group). Statistical significance was determined using one-way ANOVA with Tukey's post hoc test, n.s. (not significant) and $***P<0.001$ vs. PT.




Fig S2. Caspase-1 is derived from microglia. Representative images showing the immunofluorescent staining of Caspase-1 with indicated cell types at Day7 after photothrombosis. The NeuN, GFAP and Iba-1 were taken as markers of neuron, astrocyte and microglia, respectively.